A Study of DA-8159 in Subjects With Erectile Dysfunction
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an
orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment
of subjects with erectile dysfunction (ED).